Bioinformatics and system biology approach to identify the influences among COVID-19, ARDS and sepsis.

Background Severe coronavirus disease 2019 (COVID -19) has led to severe pneumonia or acute respiratory distress syndrome (ARDS) worldwide. we have noted that many critically ill patients with COVID-19 present with typical sepsis-related clinical manifestations, including multiple organ dysfunction syndrome, coagulopathy, and septic shock. The molecular mechanisms that underlie COVID-19, ARDS and sepsis are not well understood. The objectives of this study were to analyze potential molecular mechanisms and identify potential drugs for the treatment of COVID-19, ARDS and sepsis using bioinformatics and a systems biology approach. Methods Three RNA-seq datasets (GSE171110, GSE76293 and GSE137342) from Gene Expression Omnibus (GEO) were employed to detect mutual differentially expressed genes (DEGs) for the patients with the COVID-19, ARDS and sepsis for functional enrichment, pathway analysis, and candidate drugs analysis. Results We obtained 110 common DEGs among COVID-19, ARDS and sepsis. ARG1, FCGR1A, MPO, and TLR5 are the most influential hub genes. The infection and immune-related pathways and functions are the main pathways and molecular functions of these three diseases. FOXC1, YY1, GATA2, FOXL, STAT1 and STAT3 are important TFs for COVID-19. mir-335-5p, miR-335-5p and hsa-mir-26a-5p were associated with COVID-19. Finally, the hub genes retrieved from the DSigDB database indicate multiple drug molecules and drug-targets interaction. Conclusion We performed a functional analysis under ontology terms and pathway analysis and found some common associations among COVID-19, ARDS and sepsis. Transcription factors-genes interaction, protein-drug interactions, and DEGs-miRNAs coregulatory network with common DEGs were also identified on the datasets. We believe that the candidate drugs obtained in this study may contribute to the effective treatment of COVID-19.

Identification and analysis of odor-active compounds from Choerospondias axillaris (Roxb.) Burtt et Hill with different moisture content levels and lacquer treatments.

The problem of indoor odors can greatly affect a room's occupants. To identify odorants and comprehensively evaluate emissions from wooden materials, emissions and odors from Choerospondias axillaris (Roxb.) Burtt et Hill with different moisture content percentages and lacquer treatments were investigated in this study. Thermal desorption-gas chromatography-mass spectroscopy/olfactometry was used to analyze the release characteristics. In total, 11 key odor-active compounds were identified as moisture content gradually decreased, concentrating between 15 and 33 min. Total volatile organic compounds, total very volatile organic compounds, and total odor intensity decreased as moisture content decreased. In addition, 35 odor-active compounds, including aromatics, alkenes, aldehydes, esters, and alcohols, were identified in the odor control list. Polyurethane (PU), ultraviolet (UV), and waterborne coatings had a good inhibitory effect on eight odor characteristics, but some scents arose after lacquer treatment. For equilibrium moisture content, the major characteristics of Choerospondias axillaris were fragrant (9.4) and mint-like (3.0) compared with the fragrant (8.2), fruity (7.8), and pleasant (5.8) characteristics of PU coating; the flowery (5.9), fragrant (5.0), glue-like (4.3), and pineapple-like (4.3) characteristics of UV coating; and the antiseptic solution (3.6), fragrant (2.9), cigarette-like (2.8), and fruity (2.5) characteristics of waterborne coating. Based on multicomponent evaluation, a Choerospondias axillaris board with waterborne coating was suggested for use indoors.

Expert consensus on protocol of rehabilitation for COVID-19 patients using framework and approaches of WHO International Family Classifications.

Coronavirus disease 2019 (COVID-19) has widely spread all over the world and the numbers of patients and deaths are increasing. According to the epidemiology, virology, and clinical practice, there are varying degrees of changes in patients, involving the human body structure and function and the activity and participation. Based on the World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) and its biopsychosocial model of functioning, we use the WHO Family of International Classifications (WHO-FICs) framework to form an expert consensus on the COVID-19 rehabilitation program, focusing on the diagnosis and evaluation of disease and functioning, and service delivery of rehabilitation, and to establish a standard rehabilitation framework, terminology system, and evaluation and intervention systems based the WHO-FICs.